关键词：反义；RNAi疗法；创新；治疗选择；慢性疾病；罕见疾病
摘 要：Antisense and RNAi therapeutics are new innovative therapeutic options that can be used for the treatment of serious chronic and rare diseases. RNAi is an RNA-based gene silencing process in which RNA molecules inhibit gene expression by destroying specific mRNA molecules. Antisense technology involves the synthesis of a strand of nucleic acid that would bind to the disease-causing mRNA. It binds to the mRNA or to a splicing site on the pre-mRNA and inactivates it effectively. RNAi and antisense are two of the predominant technologies used by pharmaceutical companies, research institutes, and others for various applications in research, diagnostics, and therapeutics. RNAi therapeutics offers a wide scope in the treatment of diseases such as cancer and neurodegenerative diseases. Two types of RNA molecules are used in RNAi technology: miRNA and siRNA. RNAi molecules bind to other specific RNAs in the cell, such as mRNA, to manage their activity to treat the RNA-mediated disorder.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Market Segmentation by Technology

08. Market Segmentation by Therapeutic Area

09. Geographical Segmentation

09.1 Antisense and RNAi Therapeutics Market in

Americas

09.1.1 Market Size and Forecast

09.2 Antisense and RNAi Therapeutics Market in EMEA

Region

09.2.1 Market Size and Forecast

09.3 Antisense and RNAi Therapeutics Market in

APAC Region

09.3.1 Market Size and Forecast

10. Buying Criteria

11. Pipeline Snapshot

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions and Collaborations

18.2 Vendor Analysis 2014

18.3 Other Prominent Vendors

19. Key Vendor Analysis

19.1 Alnylam Pharmaceuticals

19.1.1 Key Facts .

19.1.2 Business Overview

Business 19.1.3 Segmentation

19.1.4 Net Revenues from Collaborators 2013

19.1.5 Business Strategy

19.1.6 Key Developments

19.1.7 SWOT Analysis

19.2 Isis Pharmaceuticals

19.2.1 Key Facts

19.2.2 Business Overview

19.2.3 Revenue Comparison 2011and 2013

19.2.4 Recent Developments

19.2.5 SWOT Analysis

19.3 Sanofi

19.3.1 Key Facts

19.3.2 Business Description

19.3.3 Business Segmentation

19.3.4 Revenue by Business Segmentation

19.3.5 Revenue Comparison 2012 and 2013

19.3.6 Sales by Geograph

19.3.7 Business Strategy

19.3.8 Key Developments

19.3.9 SWOT Analysis

19.4 Tekmira Pharmaceuticals

19.4.1 Key Facts

19.4.2 Business Overview

19.4.3 Financial Performance

19.4.4 Key Developments

19.4.5 SWOT Analysis

20. Other Reports in this Series